糖尿病药物作为全球慢病管理的核心治疗手段,其市场规模一直在持续扩容与迭代。与此同时,众多国内医药企业、机构也在不断加码布局该领域。据悉,2026年1月以来,国内外药企及机构在糖尿病领域的新药临床突破、商业上市方面已迎来不少重要进展。近日,歌礼制药宣布其口服小分子GLP-1受体(GLP-1R)激动剂ASC30治疗2型糖尿病的美国13周II期研究(NCT07321678)已完成首批受试者给药。预计将于...
Source Link糖尿病药物作为全球慢病管理的核心治疗手段,其市场规模一直在持续扩容与迭代。与此同时,众多国内医药企业、机构也在不断加码布局该领域。据悉,2026年1月以来,国内外药企及机构在糖尿病领域的新药临床突破、商业上市方面已迎来不少重要进展。近日,歌礼制药宣布其口服小分子GLP-1受体(GLP-1R)激动剂ASC30治疗2型糖尿病的美国13周II期研究(NCT07321678)已完成首批受试者给药。预计将于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.